by James DeFranco | May 25, 2022 | Uncategorized
Are you ready for Butalbital/APAP combination products to become a Controlled Substance? Written-by: Deneen Fumich, RPh On April 12, 2022, the Drug Enforcement Administration “DEA” published in the Federal Register a Notice of Proposed Rulemaking. The DEA proposed to...
by James DeFranco | May 2, 2022 | Uncategorized
FDA Proposed Rules Review, Part 3 of 4: WDD Licensing Standards & Approved Organizations Oversight Written-by: Sumeet Singh, CEO In this third part of the review of FDA’s proposed rules, we focus on the national standards FDA seeks to levy on Wholesale Drug...
by James DeFranco | Apr 6, 2022 | Uncategorized
Nevada to Require Nonresident Pharmacists To Obtain Licensure Written-by: Deneen Fumich, RPh Nevada Reinterpreted NRS 639.100(1)(a) to Require Nonresident Pharmacist Licensure Late last year, Nevada reinterpreted its enforcement of NRS 639.100(1)(a) to require...
by James DeFranco | Apr 6, 2022 | Uncategorized
Puerto Rico Product Registration: Undocumented Rule and Enforcement Change Written-by: Deneen Fumich, RPh Understanding Registration Basics Pursuant to Puerto Rico Chapter 5, Article 5.01 Manufacturing, Distribution and Dispensing of Drugs, each pharmaceutical...
by James DeFranco | Mar 30, 2022 | Uncategorized
3 The Complexities and Application of Drug Takeback Programs Written-by: Deneen Fumich, RPh Pre-Article Comment: For those Health Care Practitioners and Pharmacies that are not located in any of the jurisdictions with a Producer/Manufacturer Funded Drug Takeback...